Milestone Pharmaceuticals (NASDAQ:MIST) Upgraded to "Buy" at HC Wainwright

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) was upgraded by equities research analysts at HC Wainwright to a "buy" rating in a research note issued on Thursday, MarketBeat reports. The brokerage currently has a $5.00 price target on the stock. HC Wainwright's price target indicates a potential upside of 183.29% from the company's current price.

MIST has been the subject of several other research reports. TD Cowen downgraded Milestone Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, April 1st. TD Securities lowered shares of Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Tuesday, April 1st. Finally, Cowen lowered shares of Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Tuesday, April 1st. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, Milestone Pharmaceuticals has a consensus rating of "Hold" and an average price target of $7.00.

Milestone Pharmaceuticals Trading Up 0.9%

Milestone Pharmaceuticals stock traded up $0.02 during mid-day trading on Thursday, hitting $1.77. The company's stock had a trading volume of 61,746 shares, compared to its average volume of 1,785,321. The company has a debt-to-equity ratio of 2.18, a current ratio of 15.40 and a quick ratio of 15.40. The stock has a market cap of $94.36 million, a price-to-earnings ratio of -2.18 and a beta of 0.92. The business has a 50 day moving average price of $1.22 and a 200-day moving average price of $1.69. Milestone Pharmaceuticals has a 12 month low of $0.63 and a 12 month high of $2.75.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.12). As a group, analysts forecast that Milestone Pharmaceuticals will post -0.62 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Propel Bio Management LLC bought a new position in shares of Milestone Pharmaceuticals during the first quarter valued at approximately $1,161,000. Toronto Dominion Bank bought a new position in shares of Milestone Pharmaceuticals in the 4th quarter worth approximately $1,770,000. Boxer Capital Management LLC bought a new position in shares of Milestone Pharmaceuticals in the 4th quarter worth approximately $729,000. Walleye Capital LLC bought a new position in shares of Milestone Pharmaceuticals in the 1st quarter worth approximately $74,000. Finally, Virtu Financial LLC bought a new position in shares of Milestone Pharmaceuticals in the 4th quarter worth approximately $170,000. Institutional investors own 86.18% of the company's stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.